Australia's CSL sees profit at top of range

MELBOURNE, Oct 15 (Reuters) - CSL Ltd (CSL.AX), the world's top maker of plasma products, said its profit for this year would be at the top end of a previously forecast range.

CSL said in August it expected its net profit this year to rise by 15-21 percent to between A$810 million ($566 million) and A$850 million, based on constant currency.

It said that if currency rates on Oct. 13 applied for the rest of the year, profit would be in the order of A$935 million to A$1.01 billion.

Analysts on average are expecting a net profit of A$899 million, according to Reuters Estimates, partly due to a 38 percent slide in the Australian dollar since the end of the last financial year.

The group, which also makes vaccines, is awaiting approval from U.S. anti-trust regulators for its $3.1 billion purchase of smaller rival Talecris BioTherapeutics from its private equity owners. ($1=A$1.43) (Reporting by Sonali Paul)